Member Info for Energyshares

Yes Stodgy only as a consultant.
Read this:
https://www.scotsman.com/sport/football/international/craig-levein-former-hearts-and-scotland-boss-opens-up-on-brechin-city-role-going-for-jobs-in-uae-and-india-and-excitement-for-euro-2020-3271046?amp

From Interim Results RNS:

Avacta's direct sales efforts are focused on large businesses, primarily but not exclusively in the UK, for workforce testing and on a range of other users of professional use tests such as elite professional sports teams and the travel industry.

Now Avacta Diagnostics new twitter account only follows 45 people, companies or organisations all of which are industry related ie: other diagnostic companies, pharma companies,organisations like WHO or Avacta employees.
All except one Craig Levein.
He was manager of Hearts and also former manager of the Scottish National team.
He has a lot of influence with SPL.

Seems a bit random with the other 44 accounts they are following.Could this be their elite sports team link..

Sorry Vegas
Great film Matt Damonnnn was good.
:)

Mr Ripley your posts for a newbie are superb.
The Talented Mr Ripley. :)

AVA004 Interesting read

William Bachovchin involved.

https://cancerres.aacrjournals.org/content/81/13_Supplement/1866

NDN will get on half way through journey.
Because he is the Bus Inspector checking tickets. He does remind me of Blakey.
“I’ll have you Butler”. :)

I haven’t seen reference to this firm before, tucked away at the bottom of the presentation slide.
Nasdaq listing in the next few years is a cert…
The US clinical trial will also help with PR exposure to US investors.

US Investor Relations
TKDY Advisors New York
Thomas Lawrence
www.tkdyadvisors.com

tkdyAdvisors delivers trusted guidance to UK and European SMIDs seeking to navigate the U.S. capital markets. We believe many SMIDs are experiencing declining buy-side exposure as MiFID II reduces the number of analyst and sell-side coverage relationships across international markets. With our deep understanding of U.S. capital markets from an international perspective, tkdyAdvisors re-imagines corporate access and helps the best UK & European SMIDs navigate and project their investment cases to the largest pool of capital in the world.

With HUA expected to land at any time.
Jupiter are taking a big risk with their short still open.

With positive results in phase 1a, I hope AS would look for a licence deal to take it further and then move on to the next precision pro-drug.

Interesting in Sunday Mail,GSK have a £8 billion war chest at their disposal from next week.

From AS himself in this weeks presentation:

Ideal for preCISION tumour activation to create safer and proprietary pro-drugs.
Conservatively assume the preCISION pro-drug versions of these can achieve similar market sizes delivering 5-10% royalty to Avacta plus development milestones.

Potential for a pipeline of preCISION pro-drugs some of which have already been synthesized with an addressable market of many billions pa.
including but not limited to:
preCISION Velcade
preCIDION Paclitaxel
preCISION Oxaliplatin
preCISION Gemcitabine
preCISION Capecitabine
preCISION PARP inhibitor
preCISION PD-1 inhibitor
preCISION AKT inhibitor
preCISION Balixafortide

With AVA6000 that’s over 10 x Billion plus markets to go at.
On top of that we have TMac platform with potential of more Billion pound markets.

LGChem multi target programme about to start pre clinic.

Affyxell developing next generation stem cell treatments.

Point Biopharma
First research programme initiated.

A Diagnostic Arm generating sales.
AFFIDX multiple pipeline being rolled out of the next few years.

Plus Licence agreements with multiple partners for Affimers.

Highly trained workforce.

84 employee’s of which 50% are PHD educated.

Leeds University as a free R&D department.

Ignore the trolls keep hold of your Golden tickets the Institution Investors and Markets will wake up to Avacta’s enormous potential soon.

:)

Kn0b head meeting just finished
Two of them are out of the meeting like flash.

RNS.
ADC Therapeutics: Avacta has provided Affimer® molecules to ADC Therapeutics under the evaluation agreement. This evaluation agreement has now concluded, and ADC Therapeutics is not taking this programme further.

Presentation.
Same news but different
Wording.

(2019)collaboration and option agreement to develop affimer-conjugates combining affimer technology with (PBD)-based warhead and linker technologies (licensed by ADCT from Astra Zeneca).
Avacta has delivered binders to a target nominated by ADCT.
ADCT has carried out an evaluation and is not taking its option to develop the Affimers further.

Note: licensed by ADCT from Astra Zeneca.

Now our new CSO

Dr Fiona McLaughlin appointed as Chief Scientific Officer of the Therapeutics Division.

Fiona has also gained broad experience during her career as a Consultant, providing scientific and strategic advice to biotechs, Not-for-Profit Organisations, and Venture Capitalists in UK, Europe, USA and Australia, including helping drive oncology strategy at the CRUK/AstraZeneca Alliance Laboratory.

My point do you reckon Dr Fiona McLaughlin has come across the warhead and linker technologies from AZ in her previous consultant role.

Interesting timing her Avacta appointment and AZ has seen what Affimers can do.

First leaked news from trial could drop anytime.
Burn those shorts AS.

The Board believe that the most significant near-term value driver for the Group is the clinical data from the phase I study of AVA6000. The pre|CISION prodrug approach has the potential to complement chemotherapy and to create new oncology treatments that are affordable for all.

Agree Bella and Rad I agree with your terms point.
But in business
“Where there's a will there's a way “

LG Chem Life Sciences Board of directors must be twitching with excitement.
With what they know about affimers.

Do they carry on with their licence agreement with Avacta and pay the multi-target deal worth up to $400m or do they take out Avacta for their £300 million MCAP =$406m.

Ok they would have to pay a premium, but they would be getting exclusive rights to the affimer technology plus pre/Cision & TMac
and a diagnostics arm and all their existing licences.

Red or Black time for them.

Look at this page LG Chem partners, interesting Avacta, Daewoong & Bill & Melinda Gates foundation.

https://innovation.lgchem.com/ResearchDevelopment/Partnership.do

After my predictions yesterday
2x results correct waiting on Christmas SP

But Liverpool & PSG scored more than predicted so I will have to push Avacta
X-mas SP up to £7.50 :)

RE: PredictionsTue 11:53
PSG 1-0 Man City
Porto 1- 3 Liverpool
Avacta £5 by Christmas

With LG Chem milestone payment and whatever income comes from Affidx,
Avacta should not need to dilute or come back to the market for a cash call.
Hopefully they have enough cash until AVA6000 results.

Hope the market see this as very positive.

PSG 1-0 Man City
Porto 1- 3 Liverpool
Avacta £5 by Christmas